In BRAF-mutant cancers, BRAF-PROTACs were developed by Cullgen as compounds 12 and 23 by linking BI882370, a pan-RAF inhibitor, and vemurafinib to the CRBN thalidomide ligand [109]. Here, BRAF is linked to cancer.